Long-term outcomes of the pentaspline pulsed-field ablation catheter for the treatment of paroxysmal atrial fibrillation: results of the prospective, multicentre FARA-Freedom Study.

Authors:
Metzner A; Fiala M; Vijgen J; Ouss A; Gunawardene M and 12 more

Journal:
Europace

Publication Year: 2024

DOI:
10.1093/europace/euae053

PMCID:
PMC10932745

PMID:
38385529

Journal Information

Full Title: Europace

Abbreviation: Europace

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Cardiology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest: We have read the journal’s policy, and the authors of this manuscript have the following competing interests: Authors have served as consultants and received lecture honoraria or research grants from multiple industry partners, including Boston Scientific (the trial sponsor), Biosense Webster, Medtronic, Abbott, Lifetech, Bayer, and Bristol Myers Squibb. Additionally, the following are employees of the sponsor: A.V., A.B.A., M.J., and J.D.R."

Evidence found in paper:

"Funding This study was funded by Boston Scientific Corporation."

Evidence found in paper:

"Registration: Clinical Trials.gov Identifier: NCT05072964 (sponsor: Boston Scientific Corporation)."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025